High Grade Muscle-Invasive Urinary Bladder Cancer in A 36 Year Old Male Patient: A Case Report & Review of Literature

Authors

  • Sachin S Kadam Department of Surgical Oncology, Currae Cancer & Multispeciality Hospital, Mumbai, India
  • Rohan Jagtap Department of General & Laparoscopy Surgery, Vedant Cancer & Multispeciality Hospital, Mumbai, India
  • Tejaswini Kadam Department of Ophthalmology, Conwest & Jain Superspeciality Eye Hospital, Mumbai, India

DOI:

https://doi.org/10.30564/jor.v4i1.3866

Abstract

We are reporting a case of urothelial bladder cancer in a 36 year old male patient with no history or exposure to any risk factors. The incidence of urothelial bladder cancer is very low in young individuals i.e. below 40 years of age with reported rate of incidence around 0.1-0.4 %. Most of the times, these young individuals present with non-muscle invasive bladder cancer with low grade and low stage. As the age increases, the incidence of high grade bladder cancer increases along with it. The index case presented with high grade muscle invasive bladder cancer at the time of diagnosis without any known risk factors. The 5-year survival of urothelial bladder cancer is better in young patients (93.8 %) as compared to older people(85.1 %). Cigarette smoking is responsible for development of bladder cancer in majority of patients followed by exposure to occupational carcinogens. Role of genetic alterations in development of bladder cancer is still under research and process of urothelial bladder carcinogenesis is unanswered in young individuals.

Keywords:

Urothelial baldder cancer; High grade; Muscle invasive; Young adult; Risk factors; Prognosis

References

[1] Yossepowitch O, Dalbagni G. Transitional cell carcinoma of the bladder in young adults: presentation, natural history and outcome. J Urol 2002;168:61-66.

[2] The Global Cancer Observatory ; March, 2021; Globocan 2020.

[3] https://gco.iarc.fr/today/data/factsheets/populations/356-india-fact-sheets.pdf.

[4] Rogers, C. G., G. S. Palapattu, S. F. Shariat, P. I. Karakiewicz, P. J. Bastian, Y. Lotan, et al. 2006. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J. Urol. 175:2048-2053; discussion 2053.

[5] Ghoneim, M. A., M. M. el-Mekresh, M. A. el-Baz, I. A. el- Attar, and A. Ashamallah. 1997. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. J. Urol. 158:393- 399.

[6] El-Bolkainy, M., N. Mokhtar, M. Ghoneim, and M.Hussein. 1981. The impact of schistosomiasis on the pathology of bladder carcinoma. Cancer 48:2643- 2648.

[7] Kassouf, W., P. E. Spiess, A. Siefker-Radtke, D. Swanson, H. B. Grossman, A. M. Kamat, et al. 2007. Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder. Cancer 110:764-769.

[8] Zuiverloon TC, Abas CS, van der Keur KA, Vermeij M, Tjin SS, van Tilborg AG, et al. In- depth investigation of the molecular pathogenesis of bladder cancer in a unique 26-year old patient with extensive multifocal disease: a case report. BMC Urol. 2010; 10: 5.

[9] Yossepowitch O, Dalbagni G. Transitional cell carcinoma of the bladder in young adults: presentation, natural history and outcome. J Urol. 2002; 168: 61- 66.

[10] Lerena J, Krauel L, Garcia-Aparicio L, Vallasciani S, Suňol M, Rodó J. Transitional cell carcinoma of the bladder in children and adolescents: six-case series and review of the literature. J Pediatr Urol. 2010; 6:481-485.

[11] Stanton ML, Xiao L, Czerniak BA and Guo CC: Urothelial tumors of the urinary bladder in young patients: A clinicopathologic study of 59 cases. Arch Pathol Lab Med 137: 13371341, 2013.

[12] Fleshner NE, Herr HW, Stewart AK, Murphy GP, Mettlin C, Menck HR. The National Cancer Data Base report on bladder carcinoma. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1996;78:1505- 1513.

[13] Brookfield KF, Cheung MC, Gomez C, Yang R, Nieder AM, Lee DJ, Koniaris LG. Survival disparities among African American women with invasive bladder cancer in Florida. Cancer 2009; 115: 4196-209.

[14] Farahmand M, Almasi-Hashiani A. Epidemiology of bladder cancers in fars province, Southern Iran (2003-2008). J Kerman Uni Med Sci 2013; 20: 387- 394.

[15] Wang QH, Ji ZG, Li HZ, Fan H, Chen ZG, Shi BB, Fang Y. Clinicopathologic Comparison of Urothelial Bladder Carcinoma in Young and Elder Patients. Pathol Oncol Res 2016;22:67-70.

[16] Wild P, Giedl J, Stoehr R, Junker K, Boehm S, van Oers JM, Zwarthoff EC, Blaszyk H, Fine SW, Humphrey PA, Dehner LP, Amin MB, Epstein JI, Hartmann A. Genomic aberrations are rare in urothelial neoplasms of patients 19 years or younger. J Pathol 2007;211:18-25.

[17] Owen HC, Giedl J, Wild PJ, Fine SW, Humphrey PA, Dehner LP, Amin MB, Epstein JI, Blaszyk H, Hughes D, Hartmann A, Stoehr R, Catto JW. Low frequency of epigenetic events in urothelial tumors in young patients. J Urol 2010;184:459-463.

[18] Na SW, Yu SH, Kim KH, Hwang EC, Jung SI, Kwon DD, Kang TW. The prognosis of patients less than 40 years with bladder cancer. J Cancer Res Ther 2014;10:710-714.

[19] Paner GP, Zehnder P, Amin AM, Husain AN, Desai MM. Urothelial neoplasms of the urinary bladder occurring in young adult and pediatric patients: a comprehensive review of literature with implications for patient management. Adv Anat Pathol. 2011; 18: 79-89.

[20] Lezama-del Valle P, Jerkins GR, Rao BN, Santana VM, Fuller C, Merchant TE. Aggressive bladder carcinoma in a child. Pediatr Blood Cancer. 2004; 43: 285-288.

[21] Scott AA, Stanley W, Worsham GF, Kirkland TA Jr, Gansler T, Garvin AJ. Aggressive bladder carcinoma in an adolescent. Report of a case with immunohistochemical, cytogenetic, and flow cytometric characterization. Am J Surg Pathol. 1989; 13: 1057-1063.

Downloads

How to Cite

Kadam, S. S., Jagtap, R., & Kadam, T. (2022). High Grade Muscle-Invasive Urinary Bladder Cancer in A 36 Year Old Male Patient: A Case Report & Review of Literature. Journal of Oncology Research, 4(1), 16–19. https://doi.org/10.30564/jor.v4i1.3866

Issue

Vol. 4 , Iss. 1 (January 2022)

Article Type

Case Report

License

Copyright and Licensing

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

Journal of Oncology Research publishes accepted manuscripts under Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). Authors who submit their papers for publication by Journal of Oncology Research agree to have the CC BY-NC 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for non-commercial use. As long as you follow the license terms and original source is properly cited, anyone may copy, redistribute the material in any medium or format, remix, transform, and build upon the material.

License Policy for Reuse of Third-Party Materials

If a manuscript submitted to the journal contains the materials which are held in copyright by a third-party, authors are responsible for obtaining permissions from the copyright holder to reuse or republish any previously published figures, illustrations, charts, tables, photographs, and text excerpts, etc. When submitting a manuscript, official written proof of permission must be provided and clearly stated in the cover letter.
The editorial office of the journal has the right to reject/retract articles that reuse third-party materials without permission.

Journal Policies on Data Sharing

We encourage authors to share articles published in our journal to other data platforms, but only if it is noted that it has been published in this journal.